APO Research
Talk to an analyst

APO RESEARCH · REPORT

Poxviridae Infections Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Poxviridae Infections Drug Market Analysis and Forecast 2026-2032

26 December 2025197 pages

Choose your research edition.

Industry ResearchPoxviridae Infections Drug Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Poxviridae Infections Drug Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Poxviridae Infections Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Poxviridae Infections Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Poxviridae Infections Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Poxviridae Infections Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Poxviridae Infections Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Poxviridae Infections Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Poxviridae Infections Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Poxviridae Infections Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Poxviridae Infections Drug include Takeda Pharmaceutical Company Limited, China Biologic Products, Inc., Verrica Pharmaceuticals Inc., Tonix Pharmaceuticals Holding Corp., SIGA Technologies, Inc., N & N Pharmaceuticals Inc., EpiVax, Inc., CJ HealthCare Corp. and Chimerix, Inc., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Poxviridae Infections Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Poxviridae Infections Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Poxviridae Infections Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Poxviridae Infections Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Poxviridae Infections Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Poxviridae Infections Drug sales, projected growth trends, production technology, application and end-user industry.

Poxviridae Infections Drug Segment by Company

Takeda Pharmaceutical Company Limited

China Biologic Products, Inc.

Verrica Pharmaceuticals Inc.

Tonix Pharmaceuticals Holding Corp.

SIGA Technologies, Inc.

N & N Pharmaceuticals Inc.

EpiVax, Inc.

CJ HealthCare Corp.

Chimerix, Inc.

CEL-SCI Corporation

BioFactura, Inc.

Bavarian Nordic A/S

Poxviridae Infections Drug Segment by Type

CJ-40011

BA-368

24a

Others

Poxviridae Infections Drug Segment by Application

Hospital

Clinic

Others

Poxviridae Infections Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Poxviridae Infections Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Poxviridae Infections Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Poxviridae Infections Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Poxviridae Infections Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Poxviridae Infections Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Poxviridae Infections Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Poxviridae Infections Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CJ-40011 Major Manufacturers Table 3. BA-368 Major Manufacturers Table 4. 24a Major Manufacturers Table 5. Others Major Manufacturers Table 6. Global Poxviridae Infections Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Manufacturers Table 8. Clinic Major Manufacturers Table 9. Others Major Manufacturers Table 10. Poxviridae Infections Drug Industry Trends Table 11. Poxviridae Infections Drug Industry Drivers Table 12. Poxviridae Infections Drug Industry Opportunities and Challenges Table 13. Poxviridae Infections Drug Industry Restraints Table 14. Global Poxviridae Infections Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Poxviridae Infections Drug Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Poxviridae Infections Drug Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Poxviridae Infections Drug Revenue Market Share by Region (2021-2026) Table 18. Global Poxviridae Infections Drug Revenue Market Share by Region (2027-2032) Table 19. Global Poxviridae Infections Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global Poxviridae Infections Drug Sales by Region (2021-2026) & (K Units) Table 21. Global Poxviridae Infections Drug Sales by Region (2027-2032) & (K Units) Table 22. Global Poxviridae Infections Drug Sales Market Share by Region (2021-2026) Table 23. Global Poxviridae Infections Drug Sales Market Share by Region (2027-2032) Table 24. Global Poxviridae Infections Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Poxviridae Infections Drug Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Poxviridae Infections Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Poxviridae Infections Drug Sales Market Share by Manufacturers (2021-2026) Table 28. Global Poxviridae Infections Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global Poxviridae Infections Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Poxviridae Infections Drug Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Poxviridae Infections Drug Manufacturers, Product Type & Application Table 32. Global Poxviridae Infections Drug Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Poxviridae Infections Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Poxviridae Infections Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Poxviridae Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Poxviridae Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Poxviridae Infections Drug Revenue Market Share by Type (2021-2026) Table 39. Global Poxviridae Infections Drug Revenue Market Share by Type (2027-2032) Table 40. Global Poxviridae Infections Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global Poxviridae Infections Drug Sales by Type (2021-2026) & (K Units) Table 42. Global Poxviridae Infections Drug Sales by Type (2027-2032) & (K Units) Table 43. Global Poxviridae Infections Drug Sales Market Share by Type (2021-2026) Table 44. Global Poxviridae Infections Drug Sales Market Share by Type (2027-2032) Table 45. Global Poxviridae Infections Drug Price by Type (2021-2026) & (US$/Unit) Table 46. Global Poxviridae Infections Drug Price by Type (2027-2032) & (US$/Unit) Table 47. Global Poxviridae Infections Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Poxviridae Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Poxviridae Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Poxviridae Infections Drug Revenue Market Share by Application (2021-2026) Table 51. Global Poxviridae Infections Drug Revenue Market Share by Application (2027-2032) Table 52. Global Poxviridae Infections Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global Poxviridae Infections Drug Sales by Application (2021-2026) & (K Units) Table 54. Global Poxviridae Infections Drug Sales by Application (2027-2032) & (K Units) Table 55. Global Poxviridae Infections Drug Sales Market Share by Application (2021-2026) Table 56. Global Poxviridae Infections Drug Sales Market Share by Application (2027-2032) Table 57. Global Poxviridae Infections Drug Price by Application (2021-2026) & (US$/Unit) Table 58. Global Poxviridae Infections Drug Price by Application (2027-2032) & (US$/Unit) Table 59. Takeda Pharmaceutical Company Limited Company Information Table 60. Takeda Pharmaceutical Company Limited Business Overview Table 61. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Portfolio Table 63. Takeda Pharmaceutical Company Limited Recent Development Table 64. China Biologic Products, Inc. Company Information Table 65. China Biologic Products, Inc. Business Overview Table 66. China Biologic Products, Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. China Biologic Products, Inc. Poxviridae Infections Drug Product Portfolio Table 68. China Biologic Products, Inc. Recent Development Table 69. Verrica Pharmaceuticals Inc. Company Information Table 70. Verrica Pharmaceuticals Inc. Business Overview Table 71. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio Table 73. Verrica Pharmaceuticals Inc. Recent Development Table 74. Tonix Pharmaceuticals Holding Corp. Company Information Table 75. Tonix Pharmaceuticals Holding Corp. Business Overview Table 76. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Portfolio Table 78. Tonix Pharmaceuticals Holding Corp. Recent Development Table 79. SIGA Technologies, Inc. Company Information Table 80. SIGA Technologies, Inc. Business Overview Table 81. SIGA Technologies, Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. SIGA Technologies, Inc. Poxviridae Infections Drug Product Portfolio Table 83. SIGA Technologies, Inc. Recent Development Table 84. N & N Pharmaceuticals Inc. Company Information Table 85. N & N Pharmaceuticals Inc. Business Overview Table 86. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio Table 88. N & N Pharmaceuticals Inc. Recent Development Table 89. EpiVax, Inc. Company Information Table 90. EpiVax, Inc. Business Overview Table 91. EpiVax, Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. EpiVax, Inc. Poxviridae Infections Drug Product Portfolio Table 93. EpiVax, Inc. Recent Development Table 94. CJ HealthCare Corp. Company Information Table 95. CJ HealthCare Corp. Business Overview Table 96. CJ HealthCare Corp. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. CJ HealthCare Corp. Poxviridae Infections Drug Product Portfolio Table 98. CJ HealthCare Corp. Recent Development Table 99. Chimerix, Inc. Company Information Table 100. Chimerix, Inc. Business Overview Table 101. Chimerix, Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Chimerix, Inc. Poxviridae Infections Drug Product Portfolio Table 103. Chimerix, Inc. Recent Development Table 104. CEL-SCI Corporation Company Information Table 105. CEL-SCI Corporation Business Overview Table 106. CEL-SCI Corporation Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. CEL-SCI Corporation Poxviridae Infections Drug Product Portfolio Table 108. CEL-SCI Corporation Recent Development Table 109. BioFactura, Inc. Company Information Table 110. BioFactura, Inc. Business Overview Table 111. BioFactura, Inc. Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. BioFactura, Inc. Poxviridae Infections Drug Product Portfolio Table 113. BioFactura, Inc. Recent Development Table 114. Bavarian Nordic A/S Company Information Table 115. Bavarian Nordic A/S Business Overview Table 116. Bavarian Nordic A/S Poxviridae Infections Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Bavarian Nordic A/S Poxviridae Infections Drug Product Portfolio Table 118. Bavarian Nordic A/S Recent Development Table 119. North America Poxviridae Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 120. North America Poxviridae Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 121. North America Poxviridae Infections Drug Sales by Type (2021-2026) & (K Units) Table 122. North America Poxviridae Infections Drug Sales by Type (2027-2032) & (K Units) Table 123. North America Poxviridae Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 124. North America Poxviridae Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 125. North America Poxviridae Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 126. North America Poxviridae Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 127. North America Poxviridae Infections Drug Sales by Application (2021-2026) & (K Units) Table 128. North America Poxviridae Infections Drug Sales by Application (2027-2032) & (K Units) Table 129. North America Poxviridae Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 130. North America Poxviridae Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 131. North America Poxviridae Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 132. North America Poxviridae Infections Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 133. North America Poxviridae Infections Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 134. North America Poxviridae Infections Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 135. North America Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 136. North America Poxviridae Infections Drug Sales by Country (2027-2032) & (K Units) Table 137. North America Poxviridae Infections Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 138. North America Poxviridae Infections Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 139. United States Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 140. Canada Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 141. Mexico Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 142. Europe Poxviridae Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 143. Europe Poxviridae Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 144. Europe Poxviridae Infections Drug Sales by Type (2021-2026) & (K Units) Table 145. Europe Poxviridae Infections Drug Sales by Type (2027-2032) & (K Units) Table 146. Europe Poxviridae Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 147. Europe Poxviridae Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 148. Europe Poxviridae Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 149. Europe Poxviridae Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 150. Europe Poxviridae Infections Drug Sales by Application (2021-2026) & (K Units) Table 151. Europe Poxviridae Infections Drug Sales by Application (2027-2032) & (K Units) Table 152. Europe Poxviridae Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 153. Europe Poxviridae Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 154. Europe Poxviridae Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 155. Europe Poxviridae Infections Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 156. Europe Poxviridae Infections Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 157. Europe Poxviridae Infections Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 158. Europe Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 159. Europe Poxviridae Infections Drug Sales by Country (2027-2032) & (K Units) Table 160. Europe Poxviridae Infections Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 161. Europe Poxviridae Infections Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 162. Germany Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 163. France Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 164. U.K. Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 165. Italy Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 166. Russia Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 167. Spain Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 168. Netherlands Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 169. Switzerland Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 170. Sweden Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 171. Poland Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 172. China Poxviridae Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 173. China Poxviridae Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 174. China Poxviridae Infections Drug Sales by Type (2021-2026) & (K Units) Table 175. China Poxviridae Infections Drug Sales by Type (2027-2032) & (K Units) Table 176. China Poxviridae Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 177. China Poxviridae Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 178. China Poxviridae Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 179. China Poxviridae Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 180. China Poxviridae Infections Drug Sales by Application (2021-2026) & (K Units) Table 181. China Poxviridae Infections Drug Sales by Application (2027-2032) & (K Units) Table 182. China Poxviridae Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 183. China Poxviridae Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 184. Asia Poxviridae Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 185. Asia Poxviridae Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 186. Asia Poxviridae Infections Drug Sales by Type (2021-2026) & (K Units) Table 187. Asia Poxviridae Infections Drug Sales by Type (2027-2032) & (K Units) Table 188. Asia Poxviridae Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 189. Asia Poxviridae Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 190. Asia Poxviridae Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 191. Asia Poxviridae Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 192. Asia Poxviridae Infections Drug Sales by Application (2021-2026) & (K Units) Table 193. Asia Poxviridae Infections Drug Sales by Application (2027-2032) & (K Units) Table 194. Asia Poxviridae Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 195. Asia Poxviridae Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 196. Asia Poxviridae Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 197. Asia Poxviridae Infections Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 198. Asia Poxviridae Infections Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 199. Asia Poxviridae Infections Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 200. Asia Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 201. Asia Poxviridae Infections Drug Sales by Country (2027-2032) & (K Units) Table 202. Asia Poxviridae Infections Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 203. Asia Poxviridae Infections Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 204. Japan Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 205. South Korea Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 206. India Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 207. Australia Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 208. Taiwan Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 209. Southeast Asia Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 210. SAMEA Poxviridae Infections Drug Revenue by Type (2021-2026) & (US$ Million) Table 211. SAMEA Poxviridae Infections Drug Revenue by Type (2027-2032) & (US$ Million) Table 212. SAMEA Poxviridae Infections Drug Sales by Type (2021-2026) & (K Units) Table 213. SAMEA Poxviridae Infections Drug Sales by Type (2027-2032) & (K Units) Table 214. SAMEA Poxviridae Infections Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 215. SAMEA Poxviridae Infections Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 216. SAMEA Poxviridae Infections Drug Revenue by Application (2021-2026) & (US$ Million) Table 217. SAMEA Poxviridae Infections Drug Revenue by Application (2027-2032) & (US$ Million) Table 218. SAMEA Poxviridae Infections Drug Sales by Application (2021-2026) & (K Units) Table 219. SAMEA Poxviridae Infections Drug Sales by Application (2027-2032) & (K Units) Table 220. SAMEA Poxviridae Infections Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 221. SAMEA Poxviridae Infections Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 222. SAMEA Poxviridae Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 223. SAMEA Poxviridae Infections Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 224. SAMEA Poxviridae Infections Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 225. SAMEA Poxviridae Infections Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 226. SAMEA Poxviridae Infections Drug Sales by Country (2021-2026) & (K Units) Table 227. SAMEA Poxviridae Infections Drug Sales by Country (2027-2032) & (K Units) Table 228. SAMEA Poxviridae Infections Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 229. SAMEA Poxviridae Infections Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 230. Brazil Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 231. Argentina Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 232. Chile Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 233. Colombia Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 234. Peru Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 235. Saudi Arabia Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 236. Israel Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 237. UAE Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 238. Turkey Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 239. Iran Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 240. Egypt Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Table 241. Key Raw Materials Table 242. Raw Materials Key Suppliers Table 243. Poxviridae Infections Drug Distributors List Table 244. Poxviridae Infections Drug Customers List Table 245. Research Programs/Design for This Report Table 246. Authors List of This Report Table 247. Secondary Sources Table 248. Primary Sources List of Figures Figure 1. Poxviridae Infections Drug Image Figure 2. Global Poxviridae Infections Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Poxviridae Infections Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. CJ-40011 Image Figure 5. BA-368 Image Figure 6. 24a Image Figure 7. Others Image Figure 8. Global Poxviridae Infections Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Poxviridae Infections Drug Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Clinic Image Figure 12. Others Image Figure 13. Global Poxviridae Infections Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Poxviridae Infections Drug Revenue (2021-2032) & (US$ Million) Figure 15. Global Poxviridae Infections Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Poxviridae Infections Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Poxviridae Infections Drug Revenue Market Share by Region (2021-2032) Figure 18. Global Poxviridae Infections Drug Sales (2021-2032) & (K Units) Figure 19. Global Poxviridae Infections Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global Poxviridae Infections Drug Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Poxviridae Infections Drug Sales YoY (2021-2032) & (K Units) Figure 22. Europe Poxviridae Infections Drug Sales YoY (2021-2032) & (K Units) Figure 23. China Poxviridae Infections Drug Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) Poxviridae Infections Drug Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa Poxviridae Infections Drug Sales YoY (2021-2032) & (K Units) Figure 26. Global Poxviridae Infections Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Poxviridae Infections Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Poxviridae Infections Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Poxviridae Infections Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Poxviridae Infections Drug Revenue Market Share by Type (2021-2032) Figure 32. Global Poxviridae Infections Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global Poxviridae Infections Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Poxviridae Infections Drug Sales Market Share by Type (2021-2032) Figure 35. Global Poxviridae Infections Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Poxviridae Infections Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Poxviridae Infections Drug Revenue Market Share by Application (2021-2032) Figure 38. Global Poxviridae Infections Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global Poxviridae Infections Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Poxviridae Infections Drug Sales Market Share by Application (2021-2032) Figure 41. North America Poxviridae Infections Drug Revenue Share by Type (2021-2032) Figure 42. North America Poxviridae Infections Drug Sales Share by Type (2021-2032) Figure 43. North America Poxviridae Infections Drug Revenue Share by Application (2021-2032) Figure 44. North America Poxviridae Infections Drug Sales Share by Application (2021-2032) Figure 45. North America Poxviridae Infections Drug Revenue Share by Country (2021-2032) Figure 46. North America Poxviridae Infections Drug Sales Share by Country (2021-2032) Figure 47. Europe Poxviridae Infections Drug Revenue Share by Type (2021-2032) Figure 48. Europe Poxviridae Infections Drug Sales Share by Type (2021-2032) Figure 49. Europe Poxviridae Infections Drug Revenue Share by Application (2021-2032) Figure 50. Europe Poxviridae Infections Drug Sales Share by Application (2021-2032) Figure 51. Europe Poxviridae Infections Drug Revenue Share by Country (2021-2032) Figure 52. Europe Poxviridae Infections Drug Sales Share by Country (2021-2032) Figure 53. China Poxviridae Infections Drug Revenue Share by Type (2021-2032) Figure 54. China Poxviridae Infections Drug Sales Share by Type (2021-2032) Figure 55. China Poxviridae Infections Drug Revenue Share by Application (2021-2032) Figure 56. China Poxviridae Infections Drug Sales Share by Application (2021-2032) Figure 57. Asia Poxviridae Infections Drug Revenue Share by Type (2021-2032) Figure 58. Asia Poxviridae Infections Drug Sales Share by Type (2021-2032) Figure 59. Asia Poxviridae Infections Drug Revenue Share by Application (2021-2032) Figure 60. Asia Poxviridae Infections Drug Sales Share by Application (2021-2032) Figure 61. Asia Poxviridae Infections Drug Revenue Share by Country (2021-2032) Figure 62. Asia Poxviridae Infections Drug Sales Share by Country (2021-2032) Figure 63. SAMEA Poxviridae Infections Drug Revenue Share by Type (2021-2032) Figure 64. SAMEA Poxviridae Infections Drug Sales Share by Type (2021-2032) Figure 65. SAMEA Poxviridae Infections Drug Revenue Share by Application (2021-2032) Figure 66. SAMEA Poxviridae Infections Drug Sales Share by Application (2021-2032) Figure 67. SAMEA Poxviridae Infections Drug Revenue Share by Country (2021-2032) Figure 68. SAMEA Poxviridae Infections Drug Sales Share by Country (2021-2032) Figure 69. Poxviridae Infections Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Poxviridae Infections Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • CJ-40011
  • BA-368
  • 24a
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Takeda Pharmaceutical Company Limited
  • China Biologic Products, Inc.
  • Verrica Pharmaceuticals Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • SIGA Technologies, Inc.
  • N & N Pharmaceuticals Inc.
  • EpiVax, Inc.
  • CJ HealthCare Corp.
  • Chimerix, Inc.
  • CEL-SCI Corporation
  • BioFactura, Inc.
  • Bavarian Nordic A/S

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Poxviridae Infections Drug Market by Type
  3. 1.2.1 Global Poxviridae Infections Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CJ-40011
  5. 1.2.3 BA-368
  6. 1.2.4 24a
  7. 1.2.5 Others
  8. 1.3 Poxviridae Infections Drug Market by Application
  9. 1.3.1 Global Poxviridae Infections Drug Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Clinic
  12. 1.3.4 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Poxviridae Infections Drug Market Dynamics
  1. 2.1 Poxviridae Infections Drug Industry Trends
  2. 2.2 Poxviridae Infections Drug Industry Drivers
  3. 2.3 Poxviridae Infections Drug Industry Opportunities and Challenges
  4. 2.4 Poxviridae Infections Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Poxviridae Infections Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Poxviridae Infections Drug Revenue by Region
  3. 3.2.1 Global Poxviridae Infections Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Poxviridae Infections Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Poxviridae Infections Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Poxviridae Infections Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Poxviridae Infections Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Poxviridae Infections Drug Sales by Region
  9. 3.4.1 Global Poxviridae Infections Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Poxviridae Infections Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Poxviridae Infections Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Poxviridae Infections Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Poxviridae Infections Drug Revenue by Manufacturers
  2. 4.1.1 Global Poxviridae Infections Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Poxviridae Infections Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Poxviridae Infections Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Poxviridae Infections Drug Sales by Manufacturers
  6. 4.2.1 Global Poxviridae Infections Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Poxviridae Infections Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Poxviridae Infections Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Poxviridae Infections Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Poxviridae Infections Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Poxviridae Infections Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Poxviridae Infections Drug Manufacturers, Product Type & Application
  13. 4.7 Global Poxviridae Infections Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Poxviridae Infections Drug Market CR5 and HHI
  16. 4.8.2 2025 Poxviridae Infections Drug Tier 1, Tier 2, and Tier 3
5 Poxviridae Infections Drug Market by Type
  1. 5.1 Global Poxviridae Infections Drug Revenue by Type
  2. 5.1.1 Global Poxviridae Infections Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Poxviridae Infections Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Poxviridae Infections Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Poxviridae Infections Drug Sales by Type
  6. 5.2.1 Global Poxviridae Infections Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Poxviridae Infections Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Poxviridae Infections Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Poxviridae Infections Drug Price by Type
6 Poxviridae Infections Drug Market by Application
  1. 6.1 Global Poxviridae Infections Drug Revenue by Application
  2. 6.1.1 Global Poxviridae Infections Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Poxviridae Infections Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Poxviridae Infections Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Poxviridae Infections Drug Sales by Application
  6. 6.2.1 Global Poxviridae Infections Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Poxviridae Infections Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Poxviridae Infections Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Poxviridae Infections Drug Price by Application
7 Company Profiles
  1. 7.1 Takeda Pharmaceutical Company Limited
  2. 7.1.1 Takeda Pharmaceutical Company Limited Company Information
  3. 7.1.2 Takeda Pharmaceutical Company Limited Business Overview
  4. 7.1.3 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Takeda Pharmaceutical Company Limited Poxviridae Infections Drug Product Portfolio
  6. 7.1.5 Takeda Pharmaceutical Company Limited Recent Developments
  7. 7.2 China Biologic Products, Inc.
  8. 7.2.1 China Biologic Products, Inc. Company Information
  9. 7.2.2 China Biologic Products, Inc. Business Overview
  10. 7.2.3 China Biologic Products, Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 China Biologic Products, Inc. Poxviridae Infections Drug Product Portfolio
  12. 7.2.5 China Biologic Products, Inc. Recent Developments
  13. 7.3 Verrica Pharmaceuticals Inc.
  14. 7.3.1 Verrica Pharmaceuticals Inc. Company Information
  15. 7.3.2 Verrica Pharmaceuticals Inc. Business Overview
  16. 7.3.3 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Verrica Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio
  18. 7.3.5 Verrica Pharmaceuticals Inc. Recent Developments
  19. 7.4 Tonix Pharmaceuticals Holding Corp.
  20. 7.4.1 Tonix Pharmaceuticals Holding Corp. Company Information
  21. 7.4.2 Tonix Pharmaceuticals Holding Corp. Business Overview
  22. 7.4.3 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Tonix Pharmaceuticals Holding Corp. Poxviridae Infections Drug Product Portfolio
  24. 7.4.5 Tonix Pharmaceuticals Holding Corp. Recent Developments
  25. 7.5 SIGA Technologies, Inc.
  26. 7.5.1 SIGA Technologies, Inc. Company Information
  27. 7.5.2 SIGA Technologies, Inc. Business Overview
  28. 7.5.3 SIGA Technologies, Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 SIGA Technologies, Inc. Poxviridae Infections Drug Product Portfolio
  30. 7.5.5 SIGA Technologies, Inc. Recent Developments
  31. 7.6 N & N Pharmaceuticals Inc.
  32. 7.6.1 N & N Pharmaceuticals Inc. Company Information
  33. 7.6.2 N & N Pharmaceuticals Inc. Business Overview
  34. 7.6.3 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 N & N Pharmaceuticals Inc. Poxviridae Infections Drug Product Portfolio
  36. 7.6.5 N & N Pharmaceuticals Inc. Recent Developments
  37. 7.7 EpiVax, Inc.
  38. 7.7.1 EpiVax, Inc. Company Information
  39. 7.7.2 EpiVax, Inc. Business Overview
  40. 7.7.3 EpiVax, Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 EpiVax, Inc. Poxviridae Infections Drug Product Portfolio
  42. 7.7.5 EpiVax, Inc. Recent Developments
  43. 7.8 CJ HealthCare Corp.
  44. 7.8.1 CJ HealthCare Corp. Company Information
  45. 7.8.2 CJ HealthCare Corp. Business Overview
  46. 7.8.3 CJ HealthCare Corp. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 CJ HealthCare Corp. Poxviridae Infections Drug Product Portfolio
  48. 7.8.5 CJ HealthCare Corp. Recent Developments
  49. 7.9 Chimerix, Inc.
  50. 7.9.1 Chimerix, Inc. Company Information
  51. 7.9.2 Chimerix, Inc. Business Overview
  52. 7.9.3 Chimerix, Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Chimerix, Inc. Poxviridae Infections Drug Product Portfolio
  54. 7.9.5 Chimerix, Inc. Recent Developments
  55. 7.10 CEL-SCI Corporation
  56. 7.10.1 CEL-SCI Corporation Company Information
  57. 7.10.2 CEL-SCI Corporation Business Overview
  58. 7.10.3 CEL-SCI Corporation Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 CEL-SCI Corporation Poxviridae Infections Drug Product Portfolio
  60. 7.10.5 CEL-SCI Corporation Recent Developments
  61. 7.11 BioFactura, Inc.
  62. 7.11.1 BioFactura, Inc. Company Information
  63. 7.11.2 BioFactura, Inc. Business Overview
  64. 7.11.3 BioFactura, Inc. Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 BioFactura, Inc. Poxviridae Infections Drug Product Portfolio
  66. 7.11.5 BioFactura, Inc. Recent Developments
  67. 7.12 Bavarian Nordic A/S
  68. 7.12.1 Bavarian Nordic A/S Company Information
  69. 7.12.2 Bavarian Nordic A/S Business Overview
  70. 7.12.3 Bavarian Nordic A/S Poxviridae Infections Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Bavarian Nordic A/S Poxviridae Infections Drug Product Portfolio
  72. 7.12.5 Bavarian Nordic A/S Recent Developments
8 North America
  1. 8.1 North America Poxviridae Infections Drug Market Size by Type
  2. 8.1.1 North America Poxviridae Infections Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Poxviridae Infections Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Poxviridae Infections Drug Price by Type (2021-2032)
  5. 8.2 North America Poxviridae Infections Drug Market Size by Application
  6. 8.2.1 North America Poxviridae Infections Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Poxviridae Infections Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Poxviridae Infections Drug Price by Application (2021-2032)
  9. 8.3 North America Poxviridae Infections Drug Market Size by Country
  10. 8.3.1 North America Poxviridae Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Poxviridae Infections Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Poxviridae Infections Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Poxviridae Infections Drug Market Size by Type
  2. 9.1.1 Europe Poxviridae Infections Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Poxviridae Infections Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Poxviridae Infections Drug Price by Type (2021-2032)
  5. 9.2 Europe Poxviridae Infections Drug Market Size by Application
  6. 9.2.1 Europe Poxviridae Infections Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Poxviridae Infections Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Poxviridae Infections Drug Price by Application (2021-2032)
  9. 9.3 Europe Poxviridae Infections Drug Market Size by Country
  10. 9.3.1 Europe Poxviridae Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Poxviridae Infections Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Poxviridae Infections Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Poxviridae Infections Drug Market Size by Type
  2. 10.1.1 China Poxviridae Infections Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Poxviridae Infections Drug Sales by Type (2021-2032)
  4. 10.1.3 China Poxviridae Infections Drug Price by Type (2021-2032)
  5. 10.2 China Poxviridae Infections Drug Market Size by Application
  6. 10.2.1 China Poxviridae Infections Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Poxviridae Infections Drug Sales by Application (2021-2032)
  8. 10.2.3 China Poxviridae Infections Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Poxviridae Infections Drug Market Size by Type
  2. 11.1.1 Asia Poxviridae Infections Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Poxviridae Infections Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Poxviridae Infections Drug Price by Type (2021-2032)
  5. 11.2 Asia Poxviridae Infections Drug Market Size by Application
  6. 11.2.1 Asia Poxviridae Infections Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Poxviridae Infections Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Poxviridae Infections Drug Price by Application (2021-2032)
  9. 11.3 Asia Poxviridae Infections Drug Market Size by Country
  10. 11.3.1 Asia Poxviridae Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Poxviridae Infections Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Poxviridae Infections Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Poxviridae Infections Drug Market Size by Type
  2. 12.1.1 SAMEA Poxviridae Infections Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Poxviridae Infections Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Poxviridae Infections Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Poxviridae Infections Drug Market Size by Application
  6. 12.2.1 SAMEA Poxviridae Infections Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Poxviridae Infections Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Poxviridae Infections Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Poxviridae Infections Drug Market Size by Country
  10. 12.3.1 SAMEA Poxviridae Infections Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Poxviridae Infections Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Poxviridae Infections Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Poxviridae Infections Drug Value Chain Analysis
  2. 13.1.1 Poxviridae Infections Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Poxviridae Infections Drug Production Mode & Process
  6. 13.2 Poxviridae Infections Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Poxviridae Infections Drug Distributors
  9. 13.2.3 Poxviridae Infections Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst